Our Services

Lung Cancer

The two main types of lung cancer are non-small cell lung cancer and small cell lung cancer. The types are based on the way the cells look under a microscope. Non-small cell lung cancer is much more common than small cell lung cancer. Tobacco smoking is the most common cause of lung cancer.

A Novel Tumor DNA Damaging Drug, MSC2490484A, Given with Etoposide and Cisplatin Chemotherapy for Smal Cell Lung Cancer Clinical Trial

  • Extensive disease small cell lung cancer
  • 1st line of treatment
  • At least one measurable target lesion
  • Patients enrolled in the Phase 1b study will receive treatment with MSC2490484A + etoposide & cisplatin.
  • Patients enrolled in the Phase II study will receive MSC2490484A or placebo + etoposide & cisplatin in a 2:1 ratio
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3830 or at Tracy.Foster@stjoe.org

A Novel CDK4/6 Inhibitor for Untreated Extensive-Stage on Small Cell Lung Cancer (SCLC)

  • Extensive-stage disease
  • 1st line
  • At least one measurable target lesion
  • Patients will receive treatment with carboplatin + etopside + atezolizumab with or without trilaciclib
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3830 or at Tracy.Foster@stjoe.org

A Novel Antibody for Targeting a Highly Expressed Activating Receptor, DLL3, on Small Cell Lung Cancer (SCLC)

  • Study name: TAHOE
  • Advanced or Stage IV SCLC
  • Patients will receive treatment with rovalpituzuamb tesirine or topotecan (2:1 ratio)
  • Patients must have progressed on their first treatment which must have been platinum based
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

A Novel Antibody for Targeting a Highly Expressed Activating Receptor, DLL3, on Small Cell Lung Cancer (SCLC)

  • Study name: MERU
  • Extensive tumor burdern due to small cell lung cancer (SCLC)
  • Patients will receive treatment with rovalpituzuamb tesirine or a placebo (1:1 ratio)
  • Patients must have had a favorable outcome after at least 4 cycles of first-line platinum based chemotherapy
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

3rd generation TKI for EGFR+ Non-small Cell Lung Cancer (NSCLC) After Removal of Tumor Clinical Trial

  • Study name: “ADAURA”
  • Stage IB-IIIA EGFR+ NSCLC
  • Patients will receive treatment with AZD9291 (Tagrisso: 3rd generation TKI) or a placebo (1:1 ratio)
  • Patients must have completed surgery (tumor resection) prior to enrollment
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Immunotherapy and Anti-hyaluronan Factor for Relapsed or Refractory Non-small Cell Lung Cancer (NSCLC) Clinical Trial

  • Locally advanced or Stage IV (metastatic)
  • All patients receive treatment
  • Patients must have failed at least 1 previous platinum-based chemotherapy prior to enrolling
  • Patients need to be HA-high
  • All patients are given pembrolizumab + PEGPH20
  • Study website: www.halo101.com
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Tracy Foster, at 707-521-3836 or at Tracy.Foster@stjoe.org

Chemotherapy With or Without Anti-ErbB3 Antibody as 2nd, 3rd, or 4th Line Treatment for Non-Small Cell Lung Cancer (NSCLC) Clinical Trial

  • Stage IIIB-IV EGFR-negative
  • Heregulin Positive
  • Patients must have undergone one, two, or three prior lines of treatment
  • Patients receive treatment with chemotherapy, with or without MM-121, an anti-ErbB3 antibody (2:1 ratio)
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Sabine Ucik, at 707-521-3830 or at Sabine.Ucik@stjoe.org

MET Inhibitor for Small Cell Lung Canncer (SCLC) with MET Genetic Alteration Just in Time Clinical Trial

  • Stage IIIB-IV
  • Genetic alteration activating MET in tumor tissue and/or ctDNA (ctDNA=blood draw looking for mutations)
  • Receipt of at least one prior treatment regimen in the advanced disease setting
  • All patients receive treatment with MGCD265, an oral MET inhibitor
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3814 or at Kimberly.Young@stjoe.org

MET Inhibitor for 2nd or 3rd Line Treatment for Non-Small Cell Lung Cancer (NSCLC) with MET Genetic Alteration Just in Time Clinical Trial

  • Stage IIIB-IV
  • cMET amplification/mutation
  • Received 1-2 prior lines of treatment
  • All patients receive treatment with Capmatinib (INC280), an oral cMET inhibitor
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kimberly Young, at 707-521-3814 or at Kimberly.Young@stjoe.org

A Tissue Acquisition Study for Patients with Primary Diagnosis of Non-small Cell Lung Cancer (NSCLC)

  • No treatment
  • Receiving treatment with an anit-PD-(L)1 therapy, or already initiated treatment with anit-PD-(L)1 therapy
  • Willing to provide archived tumor specimen or willing to undergo a biopsy procedure for the purpose of obtaining tumor tissue and/or tumor cells.
  • Able to provide periodic blood samples
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the lead coordinator, Kayla Denbeste, at 707-521-3808 or at Kayla.Denbeste@stjoe.org